Please assess the completion status of the following clinical trial:

Trial Title: Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to provide a written informed consent~* Men 18 years or older with metastatic castration-resistant prostate cancer enrolling onto the Febbo clinical trial with dasatinib therapy (must meet all inclusion criteria for dasatinib treatment study and comply with requirements of that specific clinical trial)~* Histologic confirmation of original prostate cancer diagnosis~* Presence of at least one convincing bone metastasis as defined by bone scintigraphy, computed tomography (CT) scan (magnetic resonance imaging \[MRI\] if indicated), or plain X-ray~* Must currently have castrate testosterone levels (\< 50 ng/dL) from orchiectomy or maintenance on a luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist~Exclusion Criteria:~* On the nilutamide-only arm (Arm A of the clinical therapeutic trial)~  * Note: However, if a patient crosses-over from nilutamide at the time of progression to add dasatinib therapy, he may be eligible for 18F-fluoride PET imaging protocol if he meets all inclusion criteria for this trial~* Any condition that would alter the patient's mental status, prohibiting the basic understanding and/or authorization of informed consent~* A serious underlying medical condition that would otherwise impair the patient's ability to receive treatment and imaging studies~* Expected lifespan of 12 weeks or less~* Extremely poor intravenous access, prohibiting the placement of a peripheral IV line for injection of radiotracer~* Initiation of bisphosphonate therapy less than 4 weeks from the first PET scan~* Radiation treatment to bone less than 4 weeks from first PET scan~* Radiopharmaceutical treatment to bone less than 4 weeks from first PET scan~* Treatment with granulocyte-macrophage colony stimulating factor (GM-CSF) or granulocyte CSF (G-CSF) within 4 weeks prior to first PET scan~* Inability to lie still for the imaging~* Weight \> 300 lbs. (due to equipment specifications)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-Fluoride PET (Type: EXPERIMENTAL): Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).